Arbutus Biopharma Corporation
ABUSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Arbutus Biopharma Corporation focuses on Biotechnology services and products. Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. At a $1.03B market cap, Arbutus Biopharma Corporation ranks as a small-cap company within healthcare. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Market Cap
$1.03B
Beta
0.62
P/E (TTM)
6.56
P/E (Fwd)
-31.34
EPS (TTM)
$0.79
EPS (Fwd)
$-0.17
ROE
89.6%
ROA
48.8%
Cash
$92.6M
Total Debt
$3.6M
Free CF
-$80.2M
52W Change
11.5%
Annual Financials
Cash vs Debt
Where ABUS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ABUS finished 13.84% above its 150-day moving average ($4.48) and 13.84% above its 200-day moving average ($4.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABUS overbought or oversold?
At the September 3, 2026 close, ABUS's RSI(14) was 71.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Arbutus Biopharma Corporation holds $92.6M in cash against $3.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$80.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 89.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 48.8% further supports the picture of efficient asset utilization. Revenue has pulled back from $39.0M (2022) to $14.1M (2025), a 64% decline worth watching.
With a beta below 0.7, Arbutus Biopharma Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ABUS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Arbutus Biopharma Corporation's trajectory.